At DDL 2022, 7- 9 December in Edinburgh, Scotland, Inhalation Sciences AB (ISAB) aims to present, for the first time, the data from its landmark study validating PreciseInhale[®] for clinical use. ISAB has now submitted an abstract of the data, that demonstrate that controlled, precision dosing of human subjects via PreciseInhale[®] outperformed aerosol dosing carried out with a standard commercial inhaler - decreasing throat deposition, decreasing standard deviation in its PK data and improving targeting of aerosols to specified major regions of the respiratory tract.

ISAB's CEO Manoush Masarrat: "Milestone data should be presented at a milestone event. DDL is all about new research that represents new paradigms and benchmarks - just like those in our Conference Paper. We have long been committed attendees and often sponsors, of DDL. After a couple of years of digital events we are eager to meet once again face-to-face with our industry peers at this packed conference. We look forward to receiving final approval of our submitted Conference Paper in September."

Twelve healthy volunteers took part in the clinical Study into PreciseInhale®, ISAB's precision dosing aerosol system. Clinical validation, which has been a long-term strategic goal for ISAB, makes PreciseInhale® the first aerosol generating system that can be used from drug discovery, through preclinical studies into first use in humans, reducing risk and translational errors throughout the drug development journey. This will, once again, show the enormous potential of ISAB's technology beyond the preclinical market with an estimated market value of 5 billion SEK.

ISAB will publish further details on its DDL Conference Paper and scheduling in September / October 2022.